AbbVie (ABBV) Tops Q1 EPS by 4c, Raises Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Abbvie (ABBV) PT Lowered to $187 at Barclays
April 29, 2024 5:22 AM EDTBarclays analyst Carter Gould lowered the price target on Abbvie (NYSE: ABBV) to $187.00 (from $195.00) while maintaining a Overweight rating.
The analyst comments "Humira erosion and transient headwinds drive reframing of '25 EPS growth, though LT profile keeps us positively biased; lowering PT to $187."
... MoreAbbVie (ABBV) hikes 2024 earnings guidance as Q1 beat estimates, shares up
April 26, 2024 7:42 AM EDTAbbVie (NYSE: ABBV) shares rose 2.4% in premarket trading Friday after the company raised full-year guidance for adjusted earnings per share (EPS) as Q1 results beat expectations.
The pharmaceutical company reported earnings per share (EPS) of $2.31 for the fiscal Q1, exceeding the consensus estimate of $2.27.... More
